Tranexamic acid for percutaneous nephrolithotomy: an abridged Cochrane review
BJU International · 2024
DOI: 10.1111/bju.16244 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJU International, 2024. Verfasst von Brent Cleveland und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Tranexamic Acid, Nephrolithotomy, Percutaneous, Antifibrinolytic Agents, Kidney Calculi. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To assess the effects of tranexamic acid (TXA) in individuals with kidney stones undergoing percutaneous nephrolithotomy (PCNL). Patients and Methods We performed a literature search of Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, grey literature, and conference proceedings. We included randomised controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients aged ≥18 years. Two review authors independently classified studies and abstracted data. Primary outcomes were blood transfusion, stone‐free rate (SFR), thromboembolic events (TEE). We rated the certainty of evidence (CoE) according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach using a minimally contextualised approach with pre‐defined thresholds for minimally clinically important differences (MCID).
Results
We included 10 RCTs assessing the effect of systemic TXA in PCNL vs placebo (or no TXA). Eight studies were published as full text. Based on an adjusted baseline risk of blood transfusion of 5.7%, systemic TXA may reduce blood transfusions (risk ratio [RR] 0.45, 95% confidence interval [CI] 0.27–0.76). Based on an adjusted baseline SFR of 75.7%, systemic TXA may increase SFR (RR 1.11, 95% CI 0.98–1.27). There is probably no difference in TEEs (risk difference 0.001, 95% CI −0.01 to 0.01). Systemic TXA may increase adverse events (AEs) (RR 5.22, 95% CI 0.52–52.72). Systemic TXA may have little to no effect on secondary interventions (RR 1.15, 95% CI 0.84–1.57). The CoE for most outcomes was assessed as low or very low.
Conclusions
Based on a body of evidence of 10 RCTs, we found that systemic TXA in PCNL may reduce blood transfusions, major surgical complications, and hospital length of stay, as well as improve the SFR; however, it may increase AEs. These findings should inform urologists and their patients in making informed decisions about the use of TXA in the setting of PCNL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Minnesota, Minneapolis, MN, USA.
- Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA.
- University of Minnesota Medical School, Minneapolis, MN, USA.
- University of Alberta, Edmonton, AB, Canada.
- Albert S. Cook Library, Towson University, Towson, MD, USA.
- Department of Surgery, Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
ORCID-Profile: Brett Norling, Philipp Dahm
Zitieren
APA
Cleveland, B., Norling, B., Wang, H., Gandhi, V., Price, C. L., Borofsky, M., Pais, V., & Dahm, P. (2024). Tranexamic acid for percutaneous nephrolithotomy: an abridged Cochrane review. BJU International. https://doi.org/10.1111/bju.16244
Vancouver
Cleveland B, Norling B, Wang H, Gandhi V, Price CL, Borofsky M, et al. Tranexamic acid for percutaneous nephrolithotomy: an abridged Cochrane review. BJU International. 2024. doi:10.1111/bju.16244
BibTeX
@article{Cleveland2024,
author = {Cleveland, Brent and Norling, Brett and Wang, Hill and Gandhi, Vardhil and Price, Carrie L and Borofsky, Michael and Pais, Vernon and Dahm, Philipp},
title = {Tranexamic acid for percutaneous nephrolithotomy: an abridged Cochrane review},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16244}
}
EUVIMED